Psychotherapy and psychosomatics · 2025
Short-Term versus Long-Term Mentalization-Based Therapy for Borderline Personality Disorder: 24 Months Follow-Up of a Randomized Clinical Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Juul Sophie, Jakobsen Janus Christian, Hestbaek Emilie, Kamp Caroline Barkholt, Olsen Markus Harboe, Rishede Marie, Frandsen Frederik Weischer, Bo Sune, Poulsen Stig, Sørensen Per, Bateman Anthony, Simonsen Sebastian
Аннотация
INTRODUCTION: Borderline personality disorder (BPD) is a severe and prevalent psychiatric disorder. Mentalization-based therapy (MBT) is an evidence-based intervention for BPD, which is often delivered as a long-term psychotherapy program for BPD. We previously published a randomized clinical trial assessing short-term versus long-term MBT for BPD 16 months after randomization as the primary follow-up time point. The objective was to assess the long-term (24 months) results of short-term versus long-term MBT for outpatients with BPD.
METHODS: Adult outpatients (≥18 years) with subthreshold or diagnosed BPD were randomly assigned (1:1) to short-term MBT (5 months) or long-term MBT (14 months). The primary outcome was BPD symptoms assessed with the Zanarini Rating Scale for Borderline Personality Disorder. Secondary outcomes were level of functioning (assessed using the Work and Social Adjustment Scale), quality of life (assessed using Short Form Health Survey, SF-36), global functioning (assessed using the Global Assessment of Functioning, GAF scale), and severe self-harm. All outcomes were assessed at 24 months after randomization.
RESULTS: Between October 4, 2018, and December 3, 2020, we randomly assigned 166 participants to short-term MBT (n = 84) or long-term MBT (n = 82). After 24 months, regression analyses showed no evidence of a difference when assessing the primary outcome, BPD symptoms (ZAN-BPD MD: -0.56; 95% CI: -2.67 to 1.54; p = 0.598), level of functioning (WSAS MD: -1.42; 95% CI: -5.04 to 2.21; p = 0.440), global functioning (GAF MD: 2.51; 95% CI: -1.65 to 6.67; p = 0.234), or severe self-harm (RR: 1.38; 95% CI: 0.88-2.21; p = 0.149). Regression analyses showed evidence of a beneficial effect of long-term MBT when assessing quality of life at 24 months (SF-36 MD: 5.52; 95% CI: 1.72-9.32; p = 0.005), but the result was potentially biased by a large proportion of missing data (40%). We found no evidence of a difference between short-term and long-term MBT on serious adverse events at 24 months (RR: 1.38; 95% CI: 0.88-2.21; p = 0.149). The serious adverse event result had no missing data.
CONCLUSION: Long-term MBT did not lead to lower levels of BPD symptoms at 24 months after randomization compared with short-term MBT. More trials comparing short-term versus long-term treatment and with fewer missing data are needed to provide better evidence-based guidance.
METHODS: Adult outpatients (≥18 years) with subthreshold or diagnosed BPD were randomly assigned (1:1) to short-term MBT (5 months) or long-term MBT (14 months). The primary outcome was BPD symptoms assessed with the Zanarini Rating Scale for Borderline Personality Disorder. Secondary outcomes were level of functioning (assessed using the Work and Social Adjustment Scale), quality of life (assessed using Short Form Health Survey, SF-36), global functioning (assessed using the Global Assessment of Functioning, GAF scale), and severe self-harm. All outcomes were assessed at 24 months after randomization.
RESULTS: Between October 4, 2018, and December 3, 2020, we randomly assigned 166 participants to short-term MBT (n = 84) or long-term MBT (n = 82). After 24 months, regression analyses showed no evidence of a difference when assessing the primary outcome, BPD symptoms (ZAN-BPD MD: -0.56; 95% CI: -2.67 to 1.54; p = 0.598), level of functioning (WSAS MD: -1.42; 95% CI: -5.04 to 2.21; p = 0.440), global functioning (GAF MD: 2.51; 95% CI: -1.65 to 6.67; p = 0.234), or severe self-harm (RR: 1.38; 95% CI: 0.88-2.21; p = 0.149). Regression analyses showed evidence of a beneficial effect of long-term MBT when assessing quality of life at 24 months (SF-36 MD: 5.52; 95% CI: 1.72-9.32; p = 0.005), but the result was potentially biased by a large proportion of missing data (40%). We found no evidence of a difference between short-term and long-term MBT on serious adverse events at 24 months (RR: 1.38; 95% CI: 0.88-2.21; p = 0.149). The serious adverse event result had no missing data.
CONCLUSION: Long-term MBT did not lead to lower levels of BPD symptoms at 24 months after randomization compared with short-term MBT. More trials comparing short-term versus long-term treatment and with fewer missing data are needed to provide better evidence-based guidance.